Skip to main content
. 2017 Nov;9(Suppl 15):S1458–S1473. doi: 10.21037/jtd.2017.03.82

Figure 4.

Figure 4

Diagnostic utility of a blood-based circulating neuroendocrine tumor gene assay—the 51 marker gene NETest—in bronchopulmonary NETs. Transcripts are elevated in 94% in both typical and atypical tumors. Chromogranin A (CgA) in contrast is only positive (elevated beyond normal levels) in 40%. Typical carcinoids are positive in (36%) and atypical tumors positive (46%).